Analysis of the concept pedophilia and orientation demonstrated that these concepts are not derived from biological and medical science, but to social actions against our religious and legal ...repression of homosexual acts in the Jewish and especially later in the Christian culture. The findings require a completely new understanding in how we manage these concepts. How we use these terms today is a danger to legal certainty, research and therapy.
Synet på barnets seksualitet må tages op til ny overvejelse. For at kunne udvikle en sund seksualitet er det nødvendigt at erkende, at seksualitet er til stede fra fødslen. Mangel på positiv spejling ...kan føre til narcissistisk raseri, som finder udtryk i seksuelle voldshandlinger.
In order to develope a healthy sexuality we have to reconsider childhood sexuality in terms of being sexual from birth. Lack of positive mirroring may develope into narcissistic rage expressed in sexual violence.
Synet på barnets seksualitet må tages op til ny overvejelse. For at kunne udvikle en sund seksualitet er det nødvendigt at erkende, at seksualitet er til stede fra fødslen. Mangel på positiv spejling ...kan føre til narcissistisk raseri, som finder udtryk i seksuelle voldshandlinger.
Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for ...VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has been observed in clinical practice, but data on this potential side effect are lacking.
The study aimed to evaluate development of fatigue in patients treated for VTE, comparing rivaroxaban to other anticoagulants.
Patients were prospectively recruited after a diagnosis of VTE. The Fatigue Questionnaire was used to determine the level of fatigue at baseline, at 3 weeks of treatment, and either at 1 month after the discontinuation of treatment if the treatment was discontinued after 3 months or at 6 months if treatment was continued beyond this time. Data was analyzed by a linear mixed model.
A total of 126 patients were included. Mean age was 59 years; 77 (61%) were males. Fifty‐seven patients (45%) were diagnosed with deep vein thrombosis, 48 (38%) with pulmonary embolism, and 21 (17%) with both. Predicted changes in fatigue scores from baseline to the last measurement were −0.007 and −2.49 for the rivaroxaban and the other‐anticoagulants groups, respectively, neither of which were statistically significant. No difference was detected between rivaroxaban and the other‐anticoagulants group at any time point, including subgroup analysis comparing over and under 6 months of treatment duration.
In this small study, our results suggest no increase in the level of fatigue after the initiation of treatment with rivaroxaban for VTE.
PDF
